WASHINGTON, July 26, 2024 — GO2 for Lung Cancer presented Pasi A. Jӓnne, M.D, Ph.D. with the 2024 Bonnie J. Addario Lectureship Award for his commitment and dedication to research and development of therapeutic strategies for patients with epidermal growth [...]
Changes could impact an additional 5 million people at higher risk for lung cancer WASHINGTON, July 9, 2024 – In its ongoing public health partnership, GO2 for Lung Cancer, the American College of Radiology (ACR) and The Society of Thoracic [...]
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer Although most lung cancer cases happen at an older age and are associated with a history of smoking, a growing number of people are diagnosed who do [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]
Clinical Trial Aims to Unlock the Origins of Lung Cancer WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), [...]
Brings background in data, AI, and analytics to help guide research collaboration and improved patient outcomes WASHINGTON, April 15, 2024 — GO2 for Lung Cancer (GO2) announced that the organization elected Fern Halper, Ph.D. to its board of directors. Halper is [...]
Congratulations to our 2024 Lung Cancer Support Group Facilitator award recipient, Christine Conti, from Huntington Health in Pasadena, California. This award, given annually since 2009, recognizes the uncommon dedication of support group facilitators. Christine Conti, RN, ONN-CG, is a thoracic [...]